ReviewImmunological reviews2025
Ontogenetic Diversification of Type 2 Conventional Dendritic Cells in the Bone Marrow: A Central Logic for Peripheral Immunity.
Review in Immunological reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dendritic-cell diversity in equine blood revealed by single-cell transcriptomics.Discovery immunology · 2026Article
- Ontogenetic Diversification of Type 2 Conventional Dendritic Cells in the Bone Marrow: A Central Logic for Peripheral Immunity.Immunological reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Type 2 conventional dendritic cells (cDC2s) are central orchestrators of adaptive immunity. While historically considered a single population shaped by local microenvironments, recent evidence indicates that cDC2s comprise developmentally distinct subsets-cDC2As and cDC2Bs-with divergent ontogeny, tissue distribution, and immune functions. This review synthesizes current advances in the identification, differentiation, and functional characterization of these cDC2 subsets, with a focus on data supporting an early bifurcation at the level of bone marrow progenitors. We highlight how transcription factors such as TCF4 (and RBPJ) and KLF4 delineate cDC2A and cDC2B fates, respectively, and how subset-specific localization within tissues may amplify their distinct roles in immunity. We propose that early cDC2 diversification reflects a broader principle of central immune preconfiguration, in which the bone marrow senses peripheral immunological states and anticipates tissue-specific demands through progenitor programming. This hypothetical model redefines cDC2s not merely as adaptable responders to local cues, but as a paradigm for how immune output can be systemically preconfigured. As such, they offer a powerful lens through which to study how development and function intersect across immunity. Recent findings suggest that the ontogenetic logic in mouse cDC2 development may extend to humans, offering meaningful avenues for translational exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.